BENGALURU (Reuters) - Pfizer Inc on Tuesday forecast US$26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination.
The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-selling product for the U.S. drugmaker in the first quarter.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
